Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 315

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 315
---
 loss, associated
with a neuronal pathology, prior to neuronal cell death as well as methods for monitoring changes in neurite destruction and synapse loss
associated with development of a neuronal pathology and monitoring the effect of a treatment on neurite destruction and synapse loss in
a subject suffering from a neuronal pathology. In addition, foreign counterparts to the U.S. patent have been granted in Canada,
Switzerland, Germany, Spain, France, United Kingdom, Ireland and Italy.

On October 31, 2017, the
USPTO issued to DiamiR U.S. Patent No.9,803,242, entitled “miRNA — Based Universal Screening Test (“UST”).”
The patent, which is set to expire on December 26, 2032, claims the use of methods developed by DiamiR for selecting subjects for
administering one or more disease-specific diagnostic tests to identify a specific pathology in the gastrointestinal (GI) system and/or
the respiratory system and/or the nervous system (and further determine if such pathology is an inflammation or cancer). On November 12,
2019, the USPTO issued to DiamiR a second U.S. Patent No. 10,472,681 with related claims directed to selecting subjects for administering
one or more disease-specific diagnostic tests to identify a specific pathology in lung or in a gastrointestinal (GI) organ, which is set
to expire on April 18, 2032. In addition, foreign counterparts to the U.S. patents have been granted in Australia, Canada, China,
Switzerland (2), Germany (2), Spain, France (2), United Kingdom (2), Ireland, Italy, and Japan.

<div align='center'>180</div>

On January 31, 2017, the
USPTO issued to DiamiR U.S. Patent No.9,556,487, entitled “Methods of using miRNA from bodily fluids for early detection and
monitoring of Mild Cognitive Impairment (“MCI”) and Alzheimer’s disease (“AD”). The patent, which is set
to expire on February 19, 2033, claims a method developed by DiamiR of treating MCI or pre-MCI in a subject without clinical symptoms
of dementia. On April 2, 2019, 2019, the USPTO issued to DiamiR a second U.S. Patent No. 10,246,747 which claims a method for
identifying a compound useful for slowing the